Akebia Therapeutics Inc (NASDAQ:AKBA)
| 0.3321 Delayed Data As of May 20 |  -0.0158 / -4.57%Today’s Change | 0.31 Today|||52-Week Range 4.33 | -85.31% Year-to-Date |
Latest AKBA News | Press Releases
| Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates May 09 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.35 |
| Today’s open | 0.36 |
| Day’s range | 0.31 - 0.37 |
| Volume | 11,523,171 |
| Average volume (3 months) | 8,648,116 |
| Market cap | $60.1M |
Data as of 4:04pm ET, 05/20/2022
Growth & Valuation
| Earnings growth (last year) | +38.46% |
| Earnings growth (this year) | +51.43% |
| Earnings growth (next 5 years) | +15.80% |
| Revenue growth (last year) | -27.68% |
| P/E ratio | NM |
| Price/Sales | 1.76 |
| Price/Book | 0.76 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BLRXBioLine RX Ltd | -0.02 | -1.93% |
| ORTXOrchard Therapeutics... | -0.01 | -2.04% |
| ADMPAdamis Pharmaceutica... | -0.03 | -7.73% |
| --Herantis Pharma Oyj | 0.00 | 0.00% |
Data as of 4:04pm ET, 05/20/2022
Financials
| Next reporting date | August 10, 2022 |
| EPS forecast (this quarter) | -$0.28 |
| Annual revenue (last year) | $213.6M |
| Annual profit (last year) | -$282.8M |
| Net profit margin | -132.43% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
